Natural product-based therapy for Cardiomyopathy: Berberine, an alkaloid isolated from the roots and bark of herbs, induces the expression of Trbp/miR-208, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene
A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study was published in the 2 June 2015 issue of the journal “Nature Genetics” (the number 1 research journal in Genetics with an impact factor of 29.648) by Prof. Da-Zhi Wang & Jian Ding, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Cardiomyopathy: Berberine, an alkaloid isolated from the roots and bark of herbs, induces the expression of Trbp/miR-208, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were: (i) due to ischemic heart disease; and (ii) expected to be doubled by 2015; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.
A number of studies suggests that Cardiomyopathy is the result of altered gene expression of contractile proteins. Trbp, an RNA binding protein, has been shown to be required for normal functioning of heart contractions. Prof Da-Zhi Wang‘s research team has shown that inactivation of Trbp in mice leads to progressive cardiomyopathy and heart failure.
This study suggests a Natural product-based therapy for Cardiomyopathy.
We have shown earlier that Berberine: (1) improves ageing- and stress-associated decline in cardiac function via up regulation of PNUTS/PPP1R10 ; (2) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes; (3) inhibits Inflammatory dilated cardiomyopathy (DCMi); and (4) inhibits senescence and extends life span.
This study suggests, for the first time, that Berberine, by increasing the expression of its target gene, it may: (1) increase the expression of Trbp and miRNA-208; (2) decrease the expression of Sox6; (3) increase the expression of cardiac slow-twitch myofiber proteins; (4) decrease the expression of skeletal fast-twitch myofiber proteins; (5) restore the balance between slow- and fast-twitch myofiber proteins; and (6)alleviate cardiomyopathy. Thus, pharmacological formulations encompassing “Berberine or its analogues” may be used to inhibit progressive cardiomyopathy and lethal heart failure. Given that Berberine can be used to treat, as discussed above, a number of related diseases-associated with cardiomyopathy and heart failure, it may be a preferable agent to treat cardiomyopathy and heart failure.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
To cite: Boominathan, Natural product therapy for Pulmonary Fibrosis: Berberine increases Toll-like receptor 4 expression and extracellular matrix glycosaminoglycan Hyaluronan levels, promotes alveolar progenitor cell renewal and repair of lung injury and prevents severe pulmonary fibrosis via down regulation of its target gene, 7/October/2015, 11.06 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org